药品详细
Triamcinolone(曲安奈德)
化学结构式图
中文名
曲安奈德
英文名
Triamcinolone
分子式
C21H27FO6
化学名
(1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-13,14,17-trihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one
分子量
Average: 394.4339
Monoisotopic: 394.179166801
Monoisotopic: 394.179166801
CAS号
124-94-7
ATC分类
A01A 未知;D07A 未知;D07X 未知;H02A 未知;R01A 未知;R03B 未知;S01B 抗炎药;C05A 未知
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739)
生产厂家
- Abbott laboratories
- Actavis mid atlantic llc
- Akorn inc
- Alcon inc
- Allergan inc
- Alpharma us pharmaceuticals division
- Altana inc
- Ambix laboratories div organics corp america
- Apothecon inc div bristol myers squibb
- Astellas pharma us inc
- Barr laboratories inc
- Bristol myers squibb co
- Bristol myers squibb co pharmaceutical research institute
- Carolina medical products co
- Del ray laboratories inc
- G and w laboratories inc
- Impax laboratories inc
- Ivax pharmaceuticals inc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Lupin atlantis holding sa switzerland
- Lyne laboratories inc
- Morton grove pharmaceuticals inc
- Mylan pharmaceuticals inc
- Parnell pharmaceuticals inc
- Perrigo new york inc
- Pharmaderm div altana inc
- Pharmafair inc
- Purepac pharmaceutical co
- Ranbaxy laboratories inc
- Roxane laboratories inc
- Sandoz canada inc
- Sandoz inc
- Sanofi aventis us llc
- Savage laboratories inc div altana inc
- Solvay pharmaceuticals
- Taro pharmaceuticals inc
- Taro pharmaceuticals usa inc
- Teva pharmaceuticals usa inc
- Topiderm inc
- Vintage pharmaceuticals llc
- Watson laboratories inc
- Wockhardt eu operations (swiss) ag
封装厂家
- AAIPharma Inc.
- Abbott Laboratories Ltd.
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- Aidarex Pharmacuticals LLC
- Alcon Laboratories
- Armstrong Pharmaceuticals Inc.
- A-S Medication Solutions LLC
- Blansett Pharmacal Co. Inc.
- Bristol-Myers Squibb Co.
- C.O. Truxton Inc.
- Carlisle Laboratories Inc.
- Carolina Medical Products Co.
- Clint Pharmaceutical Inc.
- Crown Laboratories Inc.
- Darby Dental Supply Co. Inc.
- Del Ray Dermatology
- Dept Health Central Pharmacy
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- E. Fougera and Co.
- E.R. Squibb and Sons LLC
- G & W Labs
- Generics Puerto Rico Inc.
- Genesis Pharmaceutical Inc.
- Goldline Laboratories Inc.
- Group Health Cooperative
- H.J. Harkins Co. Inc.
- Hl Moore Drug Exchange
- Ide Interstate
- Innoviant Pharmacy Inc.
- Inyx Usa Ltd.
- Keene Pharmaceuticals Inc.
- Lake Erie Medical and Surgical Supply
- Major Pharmaceuticals
- Martica Enterprises Inc.
- Martin Surgical Supply
- Medisca Inc.
- Medvantx Inc.
- Mericon
- Merit Pharmaceuticals
- National Pharmaceuticals
- Nycomed Inc.
- Paddock Labs
- Palmetto Pharmaceuticals Inc.
- Parnell Pharmaceuticals Inc.
- Perrigo Co.
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Primedics Laboratories
- Princeton Pharmaceutical Products Inc.
- Qualitest
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Robar Inc.
- San Jose Surgical Supply Inc.
- Sandoz
- Sanofi-Aventis Inc.
- Savage Labs
- Stat Rx Usa
- Suppositoria Laboratories Inc.
- Taro Pharmaceuticals USA
- Topiderm Inc.
- Vintage Pharmaceuticals Inc.
- Watson Pharmaceuticals
- Wockhardt Ltd.
- X-Gen Pharmaceuticals
参考
| Synthesis Reference | Not Available |
| General Reference | Not Available |
剂型
规格
化合物类型
| Type | small molecule |
| Classes |
|
| Substructures |
|
适应症
药理
| Indication | For the treatment of perennial and seasonal allergic rhinitis. |
| Pharmacodynamics | Triamcinolone and its derivatives are synthetic glucocorticoids that are used for their antiinflammatory or immunosuppressive properties. |
| Mechanism of action | The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. |
| Absorption | Rapid absorption following oral administration |
| Volume of distribution | Not Available |
| Protein binding | 68% |
| Metabolism |
Hepatic.
|
| Route of elimination | Not Available |
| Half life | 88 minutes |
| Clearance | Not Available |
| Toxicity | LD50=>500mg/kg (in rats) |
| Affected organisms |
|
| Pathways | Not Available |
理化性质
| Properties | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| State | solid | ||||||||||||||||||||||||||||||||||||||||||
| Experimental Properties |
|
||||||||||||||||||||||||||||||||||||||||||
| Predicted Properties |
|
||||||||||||||||||||||||||||||||||||||||||
药物相互作用
| Drug | Interaction |
|---|---|
| Acenocoumarol | The corticosteroid, triamcinolone, alters the anticoagulant effect, acenocoumarol. |
| Acetylsalicylic acid | The corticosteroid, triamcinolone, may decrease the effect of the salicylate, acetylsalicylic acid. |
| Ambenonium | The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, ambenonium. |
| Amobarbital | The barbiturate, amobarbital, may decrease the effect of the corticosteroid, triamcinolone. |
| Anisindione | The corticosteroid, triamcinolone, alters the anticoagulant effect of anisindione. |
| Aprobarbital | The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, triamcinolone. |
| Bismuth Subsalicylate | The corticosteroid, triamcinolone, may decrease the effect of the salicylate, bismuth subsalicylate. |
| Butabarbital | The barbiturate, butabarbital, may decrease the effect of the corticosteroid, triamcinolone. |
| Butalbital | The barbiturate, butalbital, may decrease the effect of the corticosteroid, triamcinolone. |
| Butethal | The barbiturate, butethal, may decrease the effect of the corticosteroid, triamcinolone. |
| Dicumarol | The corticosteroid, triamcinolone, alters the anticoagulant effect of dicumarol. |
| Dihydroquinidine barbiturate | The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone. |
| Edrophonium | The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, edrophonium. |
| Ethotoin | The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, triamcinolone. |
| Fosphenytoin | The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, triamcinolone. |
| Heptabarbital | The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, triamcinolone. |
| Hexobarbital | The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, triamcinolone. |
| Magnesium salicylate | The corticosteroid, triamcinolone, may decrease the effect of magnesium salicylate. |
| Mephenytoin | The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, triamcinolone. |
| Methohexital | The barbiturate, methohexital, may decrease the effect of the corticosteroid, triamcinolone. |
| Methylphenobarbital | The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, triamcinolone. |
| Midodrine | Increased arterial pressure |
| Neostigmine | The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, neostigmine. |
| Pentobarbital | The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, triamcinolone. |
| Phenobarbital | The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, triamcinolone. |
| Phenytoin | The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, triamcinolone. |
| Primidone | The barbiturate, primidone, may decrease the effect of the corticosteroid, triamcinolone. |
| Pyridostigmine | The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, pyridostigmine. |
| Quinidine barbiturate | The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone. |
| Rifampin | The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone. |
| Salicylate-sodium | The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salicylate-sodium. |
| Salsalate | The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salsalate. |
| Secobarbital | The barbiturate, secobarbital, may decrease the effect of the corticosteroid, triamcinolone. |
| Tacrine | Tacrine and Triamcinolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects. |
| Talbutal | The barbiturate, talbutal, may decrease the effect of the corticosteroid, triamcinolone. |
| Trastuzumab | Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. |
| Trisalicylate-choline | The corticosteroid, triamcinolone, may decrease the effect of the salicylate, trisalicylate-choline. |
| Vecuronium | Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Triamcinolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. |
| Warfarin | The corticosteroid, triamcinolone, alters the anticoagulant effect of warfarin. |
食物相互作用
Not Available
收藏